- Home
- BREA vs CYCN Comparison
BREA vs CYCN Comparison
Compare BREA & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BREA
- CYCN
- Stock Information
- Founded
- BREA 2022
- CYCN 2018
- Country
- BREA Ireland
- CYCN United States
- Employees
- BREA N/A
- CYCN N/A
- Industry
- BREA Services-Misc. Amusement & Recreation
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- BREA Consumer Discretionary
- CYCN Health Care
- Exchange
- BREA Nasdaq
- CYCN Nasdaq
- Market Cap
- BREA 13.6M
- CYCN 6.5M
- IPO Year
- BREA 2023
- CYCN N/A
- Fundamental
- Price
- BREA $8.00
- CYCN $3.14
- Analyst Decision
- BREA
- CYCN
- Analyst Count
- BREA 0
- CYCN 0
- Target Price
- BREA N/A
- CYCN N/A
- AVG Volume (30 Days)
- BREA 18.0K
- CYCN 25.9K
- Earning Date
- BREA 01-01-0001
- CYCN 08-06-2025
- Dividend Yield
- BREA N/A
- CYCN N/A
- EPS Growth
- BREA N/A
- CYCN N/A
- EPS
- BREA N/A
- CYCN N/A
- Revenue
- BREA $2,988,009.00
- CYCN $2,081,000.00
- Revenue This Year
- BREA N/A
- CYCN N/A
- Revenue Next Year
- BREA N/A
- CYCN N/A
- P/E Ratio
- BREA N/A
- CYCN N/A
- Revenue Growth
- BREA 151.51
- CYCN N/A
- 52 Week Low
- BREA $5.00
- CYCN $1.27
- 52 Week High
- BREA $19.50
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- BREA 58.26
- CYCN 52.20
- Support Level
- BREA $7.48
- CYCN $3.05
- Resistance Level
- BREA $8.59
- CYCN $3.50
- Average True Range (ATR)
- BREA 0.69
- CYCN 0.27
- MACD
- BREA 0.12
- CYCN 0.02
- Stochastic Oscillator
- BREA 78.27
- CYCN 54.43
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.